07:40 AM EDT, 05/29/2024 (MT Newswires) -- Affimed ( AFMD ) said Wednesday that the US Food and Drug Administration has granted Fast Track designation for its potential treatment of patients with advanced and/or metastatic non-small cell lung cancer without any activating epidermal growth factor receptor following targeted therapy and platinum-based chemotherapy.

The treatment combines Affimed's ( AFMD ) innate cell engager AFM24 with atezolizumab, the clinical-stage company said.

The designation was made after a review of the initial efficacy data in an ongoing phase 1/2a study as well as initial results observed in a mid-stage trial, the company added.

Shares of the biopharmaceutical company were up more than 3% in recent Wednesday premarket activity.